Gianluca Mascianà

Dr. Gianluca Mascianà


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2025 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
Francesco BrucchiFrancesco Brucchi
Francesco Brucchi
IMIsacco Montroni
Isacco Montroni
Roberto CirocchiRoberto Cirocchi
Roberto Cirocchi
GTGiovanni Taffurelli
Giovanni Taffurelli
MVMarco Vitellaro
Marco Vitellaro
SLSara Lauricella
Sara Lauricella
Purpose: The purpose of this study is to review the application of the da Vinci® Single-Port system (DVSP) in colorectal surgery, with a view to assessing its safety and feasibility, and investigating its clinical and oncological outcomes. Methods: A comprehensive search of the scientific literature was conducted across three major databases (PubMed, Web of Science, and Cochrane) up to November 2024. The study was registered in PROSPERO (CRD42024612762) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Included studies pertained to the utilisation of DVSP in the domain of colorectal surgery. Results: Eleven articles were included in the final analysis. No randomized controlled trials were identified. A total of 396 patients (199 men, 197 women) underwent robotic colorectal surgery using the DVSP. Surgical resections were indicated for benign pathology in 56 patients, colon carcinoma in 194 cases, and rectal carcinoma in 146 cases. The median incision length for Uniport placement was 4 cm. The median docking time was 5.96 min (IQR, 9.33 min), and the median console time was 105 min (IQR, 62.51 min). The mean operative time was 186.3 min (IQR, 77.65 min). Intraoperative complications were rare, with only two cases reported (0.47%). Postoperative complications occurred in 12.47% of patients, with ileus being the most common. No patients were readmitted for complications within 30 days. Short-term oncological outcomes seemed promising, with a median of 24.59 lymph nodes retrieved. There were no reported deaths within 30 days. The median follow up time was 11.4 months (IQR, 11.76 months). Conclusion: This study shows that the use of DVSP in colorectal surgery is both feasible and safe. Short-term clinical and oncological outcomes seem promising. However, longer follow-up data and larger patient cohorts are needed to fully assess the long-term efficacy of this novel technique. Prospero registry: Registration number CRD42024612762.

9 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
LLLoris Lopetuso
Loris Lopetuso
MMMarco Murgiano
Marco Murgiano
EMElisabetta Mantuano
Elisabetta Mantuano
VSVincenzo Schiavone
Vincenzo Schiavone
ACAlessandro COSTA
Alessandro COSTA
Gianluca CostaGianluca Costa
Gianluca Costa
Inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic immune-mediated disorders characterized by mucosal injury, cycles of inflammation and repair, and tissue damage. Persistent inflammation accelerates epithelial turnover, generates oxidative and replication stress, and remodels the stromal niche, contributing to the risk of colorectal cancer (CRC). Systematic dysplasia surveillance remains essential. Cellular senescence has emerged as a unifying mechanism linking inflammation, impaired epithelial repair, fibrosis, and neoplasia. In UC, p16/p21 upregulation, telomere erosion, and loss of lamin B1 accumulate and adopt a senescence-associated secretory phenotype (SASP) that perpetuates barrier dysfunction. In CD, senescence within stem and stromal compartments limits regeneration, promotes pro-fibrotic remodeling, and sustains cycles of injury and repair via chronic SASP signaling. IBD prevalence continues to rise from environmental factors, dietary changes, antibiotic exposures, and gut microbiota alterations. Pathogenesis integrates genetic factors (e.g., NOD2, IL23R, HLA, and ATG16L1 mutations), environmental modifiers, dysbiosis characterized by loss of short-chain fatty-acid-producing Gram-positive bacteria and expansion of Proteobacteria, and a dysregulated immune system. Therapeutic strategies have shifted toward targeted biologics and small molecules to promote mucosal healing. In this review, we recapitulate the mechanistic axes of inflammation, oxidative stress, and senescence in IBD and then critically evaluate emerging targeted therapies. Topics include anti-TNFα, integrin blockade, IL-12/23 and IL-23 inhibition, JAK inhibitors, S1P receptor modulators, microRNA modulation, senomorphics, mesenchymal cell therapy, and microbiome interventions. We endorse biomarker-guided therapy and propose future directions to break the SASP-driven inflammatory loop and mitigate long-term carcinogenic risk.

3 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VSVincenzo Schiavone
Vincenzo Schiavone
Filippo CarannanteFilippo Carannante
Filippo Carannante
GCGabriella Teresa Capolupo
Gabriella Teresa Capolupo
VMValentina Miacci
Valentina Miacci
Gianluca CostaGianluca Costa
Gianluca Costa
GMGianluca Mascianà
Gianluca Mascianà
Background: Robotic liver surgery is emerging as a key advancement in minimally invasive techniques, though it still faces several challenges. Meanwhile, colorectal cancer (CRC) continues to be a leading cause of cancer deaths, with liver metastases affecting 25–30% of patients. These metastases significantly burden healthcare systems by raising costs and resource demands. Methods: A narrative literature review was performed, resulting in the inclusion of 14 studies in our analysis. Fourteen studies met the inclusion criteria and were analyzed with attention to patient characteristics, surgical details, perioperative outcomes, and reporting limitations. For consistency, simultaneous robotic-assisted resection (RAR) refers to cases in which the colorectal primary and liver metastasectomy were performed during the same operative session. Results: The 14 studies included a total of 771 patients (520 males and 251 females), aged between 31 and 88, undergoing simultaneous robotic-assisted resection (RAR). Most were affected by rectal cancer (76%) and unilobar liver metastases (82%). All surgeries using the DaVinci system are represented by 62% wedge resection and 38% anatomical (21.39% major and 16.61% minor). Patients’ BMI ranged from 19.5 to 40.4 kg/m2, the average blood loss was 181.5 mL (30–780), the median hospital stay was 7 days (range 2–28), and the mean operative time ranged from 30 to 682 min. Data on POLF (postoperative liver failure) are reported in two studies: Rocca et al., 1/90 patients; Marino et al., 1/40 patients. Biliary leak is reported in one case by Marino et al., while Winckelmans et al. reported a 2.6% incidence of biliary leak in the laparoscopic group and 3.4% in the robotic group. Conclusions: As research advances and new therapies emerge for colorectal liver metastasis (CRLM), surgery remains the mainstay of treatment. However, evidence is limited by small sample sizes, heterogeneous study designs, inconsistent reporting of perioperative chemotherapy, timing of surgery, metastasis localization, and complications. Robotic liver surgery has become a well-established technique and possibly represents the future for managing colorectal liver metastases. Further prospective and comparative studies with standardized outcome reporting are needed to define optimal patient selection and long-term effectiveness.

2 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
VSVincenzo Schiavone
Vincenzo Schiavone
Filippo CarannanteFilippo Carannante
Filippo Carannante
GCGabriella Teresa Capolupo
Gabriella Teresa Capolupo
VMValentina Miacci
Valentina Miacci
Gianluca CostaGianluca Costa
Gianluca Costa
GMGianluca Mascianà
Gianluca Mascianà
Background: Robotic liver surgery is emerging as a key advancement in minimally invasive techniques, though it still faces several challenges. Meanwhile, colorectal cancer (CRC) continues to be a leading cause of cancer deaths, with liver metastases affecting 25–30% of patients. These metastases significantly strain healthcare systems by raising costs and resource demands. Methods: A narrative literature review was performed, resulting in the inclusion of 14 studies in our analysis. Results: The 14 studies included a total of 771 patients (520 males and 251 female) undergoing simultaneous robotic-assisted resection (SRAR), aged between 31 and 88. Most were affected by rectal cancer (76%) and unilobar liver metastases (82%). All surgeries used the da Vinci system, with limited resections (≤3 segments) in 83% of cases—85 minor and 45 major hepatectomies. All achieved R0 (negative margin) resections. Patients’ BMI ranged from 19.5 to 40.4 kg/m², and median hospital stay was 7 days (range 2–28). Conclusions: As research advances and new therapies emerge for Colorectal liver Metastasis (CRLM), surgery remains the mainstay of treatment. Robotic liver surgery has become a well-established technique and represents the future for managing colorectal liver metastases.

13 October 2025 in Encyclopedia
Verified
Journal Article
Open access
PDF file
VSVincenzo Schiavone
Vincenzo Schiavone
GCGabriella Teresa Capolupo
Gabriella Teresa Capolupo
GMGianluca Mascianà
Gianluca Mascianà
Filippo CarannanteFilippo Carannante
Filippo Carannante
Gianluca CostaGianluca Costa
Gianluca Costa
MCMarco Caricato
Marco Caricato
Rectal cancer has become a significant health concern in current years, but there are very effective current neo-adjuvant treatment modalities which can result in the complete disappearance of the disease without surgery, which is often associated with severe post-surgical sequelae. Therefore, a significant effort has been made to identify the subset of patients who can avoid surgery and to investigate the long-term oncologic and functional results associated with the Non-Operative Management of such a disease.

Verified
Journal Article
Open access
PDF file
VSVincenzo Schiavone
Vincenzo Schiavone
Filippo CarannanteFilippo Carannante
Filippo Carannante
GMGennaro Melone
Gennaro Melone
VMValentina Miacci
Valentina Miacci
Gianluca CostaGianluca Costa
Gianluca Costa
GMGianluca Mascianà
Gianluca Mascianà
Introduction: Colonic lipomas (CLs) are benign neoplasms originating from adipose tissue within the gastrointestinal tract. They are often asymptomatic, but in certain cases, patients may present with gastrointestinal bleeding or symptoms related to intestinal obstruction. We report the cases of 18 patients undergoing both surgical and endoscopic resection of colonic lipomas. Given the variability in symptoms, lesion size, and patient demographics, the management of CLs represents a clinical scenario where treatment must be tailored to the individual, aligning with the principles of personalized medicine. This study aims to clarify the clinical and morphological factors guiding treatment selection for colonic lipomas, emphasizing a personalized approach to management. Materials and Methods: We retrospectively reviewed a prospectively collected database of 18 patients with histological diagnosis of colon lipoma after both endoscopic and surgical resection at the Campus Bio-Medico University Hospital, Rome, from 2016 to the first months of 2025. Results: The average patient age was 66 years, and the average maximum size of lipoma was 2.87 cm. The anatomical location of lipomas is very varied, ranging from the ileocecal valve to the distal sigma, and most procedures were endoscopic. Conclusions: Despite the fact that no established guidelines about the management of the CLs are reported in literature, the different approaches are related to symptomatology. Our findings try to clarify and demonstrate how the therapeutic decision, whether endoscopic or surgical, is personalized based on the patients and their clinical condition, illustrating how CL management reflects the broader framework of personalized medicine. Our work confirms that the patients most prone to intussusception phenomena are young women with large colonic lipomas.